Date: 2020-11-04
Type of information: Nomination
Compound: business development officers
Company: Vectivbio (Switzerland)
Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation
Type agreement: nomination
Action mechanism:
Disease:
Details:
- On November 04, 2020, VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases,nannounced the appointments of Sarah Holland, Ph.D., as Chief Business Officer and Aditya Venugopal, Ph.D., as Vice President of Business Development. Dr. Holland will be based in Switzerland and Dr. Venugopal will be based in the U.S., further expanding the company’s global reach.
Dr. Holland has a strong track record of leadership. Most recently, she served as Global Head of licensing at Lonza where she built the new licensing business unit, led research and development and drove the spin-off of Affinia Therapeutics. Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D. Before that, Dr. Holland served at Roche for over a decade in positions of increasing responsibility, culminating as Life Cycle Leader for ALECENSA® (alectinib). She led many deals for Roche Partnering, including licensing ZELBORAF® (vemurafenib) from Plexxikon and establishing a key CNS partnership with PTC Therapeutics. She built the team responsible for championing and integrating company acquisitions and drove the Roche strategy for rare diseases. Dr. Holland earned an M.A. and D.Phil. in chemistry from the University of Oxford and an MBA from Manchester Business School.
Dr. Venugopal was most recently an Executive Director at Intercept Pharmaceuticals, where he held roles leading corporate strategic planning and business development. While at Intercept, he drove BD expansion efforts in hepatology and gastroenterology. Previously, he was an Associate Director at Navigant Life Science Consulting where he led global cross-functional teams focused on business development and licensing assessments in immunology, oncology and rare diseases. Dr. Venugopal earned a Ph.D. in immunology and microbiology from Cornell University Medical College and a B.E. in biotechnology from Anna University in India.
Financial terms:
Latest news:
Is general: Yes
